TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11273944
Drug: 0.05% or
Normalized name: Sodium Fluoride 0.05% Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% or 0.1% solutions of bupivacaine/fentanyl and ropivacaine/fentanyl
Study: 11273944
Drug: 0.05% solution
Normalized name: Equate Nasal Spray 0.05% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% solution
Study: 9563925
Drug: Interferon-alpha 2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha 2b alone (monotherapy)
Study: 3592847
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg oxpentifylline thrice daily for 12 weeks
Study: 3592847
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo tablets for 12 weeks
Study: 3592847
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg oxpentifylline for MID patients (n = 4)
Study: 3592847
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg oxpentifylline for PDD patients
Study: 26564446
Drug: Longitudinal changes
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longitudinal changes in corneal curvature (CC)
Study: 26564446
Drug: Correlation between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation between axial length (AL) and corneal curvature (CC)
Study: 22257825
Drug: TMZ plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMZ plus WBI (30 Gy in 10 fractions over 2 weeks with 200 mg TMZ on M/W/F and 300 mg TMZ on T/Th)
Study: 20680385
Drug: Ice water
Normalized name: CVS Electrolyte Solution with Zinc (Rice Water)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice water ingestion (250 ml)
Study: 8265878
Drug: Buspirone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (20 mg daily for 14 days)
Study: 3011023
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (6.6 g)
Study: 2890550
Drug: Olsalazine sodium
Normalized name: Olsalazine Sodium
DrugBank: Olsalazine (DB01250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olsalazine sodium 0.75 g
Study: 2890550
Drug: Olsalazine sodium
Normalized name: Olsalazine Sodium
DrugBank: Olsalazine (DB01250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olsalazine sodium 1.5 g
Study: 2890550
Drug: Olsalazine sodium
Normalized name: Olsalazine Sodium
DrugBank: Olsalazine (DB01250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olsalazine sodium 3 g
Study: 30537261
Drug: Troponin T
Normalized name: Troponin T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troponin T (TnT) elevated to >18 ng/L and NT-proBNP in the highest tertile (9% of all patients)
Study: 30537261
Drug: Troponin T
Normalized name: Troponin T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troponin T (TnT) <18 ng/L and NT-proBNP in the lowest tertile (16% of all patients)
Study: 21455612
Drug: PRT +
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PRT + fortified milk supplement
Study: 21455612
Drug: Fortified milk
Normalized name: Fortified milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified milk supplement
Study: 15330403
Drug: Psychosocial service
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial service utilization (therapy with a psychologist, self-help group, therapy with a social worker, therapy with another type of provider)
Study: 15330403
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of alcohol/drug abuse disorders
Study: 11130743
Drug: Sildenafil 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 200 mg
Study: 9228814
Drug: Ineraid cochlear
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ineraid cochlear implant with analog processing
Study: 9228814
Drug: Nucleus cochlear
Normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleus cochlear implant with feature-extraction processing
Study: 9228814
Drug: Both Ineraid
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Ineraid and Nucleus cochlear implants
Study: 8112068
Drug: Locobase (moisturizer)
Normalized name: Monobasic Potassium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locobase (moisturizer) used for 2 weeks (period L)
Study: 8112068
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (period C)
Study: 23913601
Drug: Selective infarct-related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective infarct-related artery (sIRA) infusion of tirofiban (10 g/kg body weight) through aspiration catheter followed by 12 hours of intravenous infusion (0.1 g/kg/min)
Study: 23913601
Drug: Conventional intracoronary
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intracoronary (IC) administration of tirofiban (10 g/kg body weight) through guiding catheter followed by 12 hours of intravenous infusion (0.1 g/kg/min)
Study: 23913601
Drug: sIRA infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: sIRA infusion of tirofiban
Study: 23913601
Drug: Conventional IC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional IC administration of tirofiban
Study: 18436152
Drug: IV/IA (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV/IA (0.6 mg/kg IV ≤ 60 mg, followed by 0.3 mg/kg IA ≤ 30 mg)
Study: 18436152
Drug: IA therapy
Normalized name: A cd33/cd3 bispecific t-cell engager antibody for acute myeloid leukemia therapy
DrugBank: Eluvixtamab (DB17252)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA therapy
Study: 8713772
Drug: VIDAS D‐dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIDAS D‐dimer ELISA, cut-off level of 500 ng/ml
Study: 30206824
Drug: Topical 0.25%
Normalized name: permethrin topical 0.25% topical kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.25% finasteride combined with topical 3% minoxidil
Study: 30206824
Drug: Topical 3%
Normalized name: sulfur topical 3% topical soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 3% minoxidil solution as monotherapy
Study: 30371169
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise training with lipopolysaccharide 0.1 ng/mL
Study: 30371169
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise training with lipopolysaccharide 1.0 ng/mL
Study: 27423256
Drug: TAK-063 (PDE10A
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-063 (PDE10A inhibitor)
Study: 25483462
Drug: GC FLU
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC FLU Injection
Study: 17613965
Drug: Gamma-hydroxybutyrate (GHB)
Normalized name: gamma-Hydroxybutyric acid
DrugBank: gamma-Hydroxybutyric acid (DB01440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-hydroxybutyrate (GHB) 50 mg/kg bodyweight, q.i.d.
Study: 17613965
Drug: Diazepam 0.5
Normalized name: diazepam 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.5 mg/kg bodyweight, q.i.d.
Study: 3182457
Drug: Ofloxacin 100
Normalized name: ofloxacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 100 mg bd
Study: 3182457
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg bd
Study: 31194645
Drug: Traditional three-level
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional three-level drug distribution system
Study: 26553733
Drug: Intralesional Mycobacterium
Normalized name: Mycobacterium phlei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional Mycobacterium w (Mw) vaccine
Study: 23954520
Drug: Intramuscular magnesium
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular magnesium sulphate (IMMG)
Study: 19565120
Drug: Topical benzyl
Normalized name: benzyl alcohol Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzyl benzoate (BB2 group) - two applications of 12.5% BB over 24 hours
Study: 19565120
Drug: Topical benzyl
Normalized name: benzyl alcohol Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzyl benzoate (BB1 group) - single application of 12.5% BB over 24 hours
Study: 19565120
Drug: Oral ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ivermectin (IV group) - 150‐200 microg/kg
Study: 11169174
Drug: Pulsed monochromatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed monochromatic infrared (956 nm) and red (637 nm) light therapy
Study: 11169174
Drug: Standard ulcer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ulcer therapy (Control)
Study: 793705
Drug: Antilymphocyte globulin
Normalized name: antilymphocyte immunoglobulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antilymphocyte globulin (ALG) treatment, 20 mg/kg-d intravenously for 10 days after transplantation
Study: 28375641
Drug: Curcumin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin and Boswellia serrata supplement
Study: 12738463
Drug: Liquid sodium
Normalized name: SODIUM SALICYLATE 486 g in 1 L ORAL LIQUID [AquaPrime Liquid Sodium Salicylate]
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid sodium phosphate (45 ml at 7:00 PM, 45 ml 3 hours before colonoscopy)
Study: 12738463
Drug: Tablet sodium
Normalized name: sodium fluoride Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet sodium phosphate (20 tablets at 7:00 PM, 20 tablets 3-5 hours before colonoscopy)
Study: 12738463
Drug: Tablet sodium
Normalized name: sodium fluoride Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet sodium phosphate
Study: 9061218
Drug: Azelastine eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine eye drops administered 30 min after ASCC
Study: 9061218
Drug: Azelastine eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine eye drops after 7 days of treatment, 30 min after ASCC
Study: 25846715
Drug: d-AMPH 5
Normalized name: 5-HYDROXYTRYPTOPHAN, D-
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-AMPH 5 mg/70 kg
Study: 25846715
Drug: d-AMPH 10
Normalized name: D & C YELLOW #10
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-AMPH 10 mg/70 kg
Study: 25846715
Drug: d-AMPH 20
Normalized name: D
DrugBank: Rosomidnar (DB17154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-AMPH 20 mg/70 kg
Study: 21224436
Drug: Intravenous ω‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ω‐3 polyunsaturated fatty acids (PUFAs) administered as a single dose of a lipid emulsion containing 4.1 g of ω‐3 PUFAs during HD
Study: 21224436
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) administered during HD
Study: 10886487
Drug: On-demand beta2-agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand beta2-agonist inhalation
Study: 10886487
Drug: Regular beta2-agonist
Normalized name: Insulina regular
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regular beta2-agonist inhalation
Study: 9311207
Drug: Acetated Ringer
Normalized name: ACETATED RINGER'S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetated Ringer solution containing 0.5 mmol.l‐1 of Mg2+ (Group II)
Study: 9311207
Drug: Acetated Ringer
Normalized name: ACETATED RINGER'S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetated Ringer solution containing 1.0 mmol.l‐1 of Mg2+ (Group III)
Study: 9311207
Drug: Acetated Ringer
Normalized name: ACETATED RINGER'S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetated Ringer solution containing 2.0 mmol.l‐1 of Mg2+ (Group IV)
Study: 9311207
Drug: Acetated Ringer
Normalized name: ACETATED RINGER'S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetated Ringer solution containing 4.0 mmol.l‐1 of Mg2+ (Group V)
Study: 9311207
Drug: Mg(2+)‐free acetated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg(2+)‐free acetated Ringer solution (Group I)
Study: 8451670
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no beta-blockers)
Study: 2951828
Drug: Combination fenoterol/ipratropium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination fenoterol/ipratropium
Study: 18550933
Drug: Candesartan (angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (angiotensin receptor blocker)
Study: 12439649
Drug: 2512 kJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2512 kJ (600 kcal) daily energy deficit diet (ED)
Study: 10338454
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin treatment (>/=24‐hour insulin‐glucose infusion followed by multidose subcutaneous insulin)
Study: 10338454
Drug: Routine antidiabetic
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine antidiabetic therapy (control group)
Study: 10338454
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine antidiabetic therapy)
Study: 1782080
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (two monthly cycles of intravenous doxorubicin/cyclophosphamide/5‐fluorouracil before locoregional therapy and four cycles subsequently)
Study: 1782080
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (six monthly cycles following locoregional therapy)
Study: 27817918
Drug: Krill oil
Normalized name: Krill oil
DrugBank: Krill oil (DB16615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krill oil (945 mg/day EPA + 510 mg/day DHA)
Study: 27817918
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (1000 mg/day EPA + 500 mg/day DHA)
Study: 28295445
Drug: Placebo (olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (olive oil 1500 mg/day)
Study: 27058408
Drug: Lung impedance
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung impedance (LI)‐guided treatment
Study: 22676398
Drug: Internet-based aftercare
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based aftercare program (individualized self-monitoring module and weekly 90-min chat sessions)
Study: 17416108
Drug: Ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2 x 3 g/24 hours
Study: 17416108
Drug: Ceftazidime divided
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime divided into 6 administrations of 2 x 3 g/24 hours
Study: 17416108
Drug: Modified dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified dosing regimen (1 g x 6 administrations)
Study: 15021446
Drug: Raloxifene +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene + low-dose, transdermal estrogen (RLX+E)
Study: 9552032
Drug: Simultaneous radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous radiotherapy plus chemotherapy (arm B)
Study: 7925193
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg succimer/kg body wt
Study: 7925193
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg succimer/kg body wt
Study: 9678091
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptive (OC) containing ethinylestradiol and gestodene
Study: 9678091
Drug: Monophasic oral
Normalized name: hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [Urelle]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic oral contraceptive (OC) containing ethinylestradiol and gestodene
Study: 29142143
Drug: DHA 2
Normalized name: DHA 200 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA 2 g/day
Study: 18377250
Drug: Cortical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortical stimulation (CS) delivered concurrently with rehabilitation therapy for 6 weeks, targeted by functional imaging at approximately 50% of motor movement threshold.
Study: 18377250
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (rehabilitation therapy without CS) for 6 weeks.
Study: 18377250
Drug: Cortical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortical stimulation (CS) delivered concurrently with rehabilitation therapy for 6 weeks.
Study: 16670135
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of ramipril once daily for 24 weeks
Study: 6337558
Drug: UV-B radiation
Normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV-B radiation (six daily treatments of one minimal erythemal dose (MErD) prior to starting daily applications of a 0.02% mechlorethamine ointment and thereafter one MErD weekly)
Study: 6337558
Drug: Topical applications
Normalized name: honey based topical applications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical applications of mechlorethamine (0.02% ointment) without UV-B
Study: 29749323
Drug: δ-tocotrienol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: δ-tocotrienol (300 mg twice daily)
Study: 24524367
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a (IFNβ1a) 22 mcg subcutaneous injection three times per week
Study: 20308220
Drug: Prescription of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of condoms
Study: 18173156
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Tianmeng Capsule (Control)
Study: 15804995
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) ondansetron (5 mg/m2) administered 30 min before chemotherapy and 12 hourly after chemotherapy
Study: 15804995
Drug: Orally disintegrating
Normalized name: Clozapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally disintegrating tablet (ODT) ondansetron (4-8 mg according to body surface area) administered 30 min before chemotherapy and 12 hourly after chemotherapy
Study: 12020139
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (specific mobilization techniques)
Study: 12020139
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (exercise therapy)
Study: 12020139
Drug: Continued care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued care by a general practitioner (analgesics, counseling, and education)
Study: 8551733
Drug: High-dose ACMF
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ACMF (6 cycles): 130 mg/m2 CPA, 26 mg/m2 MTX, 600 mg/m2 5-FU, 26 mg/m2 ADM
Study: 8551733
Drug: Low-dose ACMF
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ACMF (12 cycles): 65 mg/m2 CPA, 13 mg/m2 MTX, 300 mg/m2 5-FU, 13 mg/m2 ADM
Study: 2112243
Drug: D‐penicillamine 10‐12
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐penicillamine 10‐12 mg/day
Study: 2112243
Drug: Gold sodium
Normalized name: Gold Sodium Thiomalate
DrugBank: Gold (DB14154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold sodium thiomalate 50 mg intramuscularly weekly
Study: 2112243
Drug: Pulse oral
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse oral methotrexate 7.5‐15.0 mg weekly
Study: 2112243
Drug: Withdrawal rates
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal rates due to adverse drug reactions
Study: 389419
Drug: Placebo normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo normal saline (S) infusion
Study: 31434498
Drug: rt-PA treatment
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rt-PA treatment combined with fisetin
Study: 22099425
Drug: Curcumin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (1 g/d, n 46)
Study: 19007835
Drug: MMRV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRV vaccine (Priorix-Tetra)
Study: 17967669
Drug: Rocuronium 50
Normalized name: rocuronium 50 mg/5 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 50 mg mixed with 8.4% NaHCO(3) 3 mL
Study: 17967669
Drug: Rocuronium 50
Normalized name: rocuronium 50 mg/5 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 50 mg mixed with 0.9% NaCl 3 mL
Study: 8903921
Drug: Tamoxifen (20‐30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20‐30 mg/day)
Study: 2699011
Drug: Classical anaesthesia
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical anaesthesia with benzodiazepine‐analgesic (diazepam and fentanyl)
Study: 30004255
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitor (SSRI) users
Study: 10334388
Drug: Group III
Normalized name: Corticosteroids, potent (group III)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III (8 patients without hepatitis virus markers with Hb > 85 g/L)
Study: 10334388
Drug: Group IV
Normalized name: Corticosteroids, very potent (group IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group IV (11 patients without hepatitis virus markers with Hb < 75 g/L)
Study: 7492041
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy in the Gamow bag at 1.58 atmospheres absolute pressure (8.5 psi) for 40 minutes
Study: 7492041
Drug: Normobaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normobaric oxygen through a nonrebreather mask at 15 L/minute for 40 minutes
Study: 1827105
Drug: Clarithromycin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (2 x 125 mg capsules, 12-hourly)
Study: 1827105
Drug: Penicillin VK
Normalized name: PENICILLIN VK 250MG TAB
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin VK (2 x 125 mg tablets, 6-hourly)